Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 8, 2022 4:01 PM ESTUDENYCA® net sales of $45.4 million in the third quarter 2022 CIMERLI launched in the United States on October 3rd Planning underway for 2023 commercial launches of toripalimab, YUSIMRY and UDENYCA® OBI Conference call today at 5 p.m. ET
REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights:
RECENT BUSINESS HIGHLIGHTS
CIMERLI (ranibizumab-eqrn), was approved in August 2022 by... More